Decis (Importazione parallela)

Informazioni principali

  • Nome commerciale:
  • Decis (Importazione parallela)
  • Forma farmaceutica:
  • EC concentrato emulsionato
  • Utilizzare per:
  • Piante
  • Tipo di medicina:
  • Agrochimico

Documenti

  • per i professionisti:
  • Il foglio illustrativo per questo prodotto non è al momento disponibile, é possibile inviare una richiesta al nostro Servizio Clienti ed essere avvisati nel momento in cui è disponibile sulla nostra piattaforma.


    Richiedi il foglio illustrativo per i professionisti.

Localizzazione

  • Disponibile in:
  • Decis (Importazione parallela)
    Svizzera
  • Lingua:
  • italiano

Informazioni terapeutiche

  • Gruppo terapeutico:
  • Insetticida

Altre informazioni

Status

  • Fonte:
  • UFAG - Ufficio federale dell'agricoltura. OFAG - Office fédéral de l'agriculture. BLW - Bundesamt für Landwirtschaft.
  • Numero dell'autorizzazione:
  • I-3500
  • Ultimo aggiornamento:
  • 18-11-2018

Foglio illustrativo: composizione, posologia, indicazioni, interazioni, gravidanza, allattamento, effetti indesiderati, controindicazioni

Denominazione commerciale: Decis

(Importazione parallela)

Elenco dei prodotti fitosanitari (stato: 06.11.2018)

Autorizzazione revocata: Termine per la svendita: 30.11.2018, Termine per l'utilizzo: 30.11.2019

Categoria di prodotti:

Titolare dell'autorizzazione

all'estero:

Numero federale di

omologazione:

Insetticida

Bayer S.p.A.

I-3500

Principio:

Tenore:

Codice di formulazione:

Principio attivo:

Deltametrina

2.81 % 25 g/l

EC concentrato emulsionato

Applicazioni

A

Coltura

Agente

patogeno/Efficacia

Dosaggio

Restrizioni

B Lampone

Verme del lampone

Concentrazione: 0.04 %

Dose: 0.4 l/ha

Termine d'attesa: 3 Settimane

1, 2, 3, 4, 5

G Serra: Aglio

Serra: Alchechengio

Serra: Barbabietola

Serra: Carote

Serra: Cavoli a

infiorescenza

Serra: Cavoli a testa

Serra: Cavoli di

Bruxelles

Serra: Cavolo rapa

Serra: Cicoria belga

Serra: Cipolle da tavola

Serra: Cipolle dolci

Serra: Cucurbitacee

Serra: Fagioli

Serra: Fave

Serra: Mais dolce

Serra: Melanzana

Serra: Pastinaca

Serra: Peperone

Serra: Pepino

Serra: Piselli

Serra: Pomodori

Serra: Prezzemolo

Aleurodidi

Concentrazione: 0.05 %

Dose: 0.5 l/ha

Termine d'attesa: 3 Giorni

3, 4, 6

A

Coltura

Agente

patogeno/Efficacia

Dosaggio

Restrizioni

tuberoso

Serra: Rafano

rusticana / Ramolaccio

Serra: Ramolaccio

Serra: Rapa di Brassica

rapa e B. napus

Serra: Ravanello

Serra: Scalogni

Serra: Scorzonera

Serra: Sedano rapa

Serra: Topinambur

Serra: Tuberina

G Aglio

Alchechengio

Barbabietola

Carciofi

Carote

Cavoli / rape da taglio

Cavoli a infiorescenza

Cavoli a testa

Cavoli di Bruxelles

Cavolo rapa

Cicoria belga

Cima di rapa

Cipolle

Crescione

Cucurbitacee

Erbette da cucina

Fagioli

Fave

Insalate (Asteracee)

Insalate asiatiche

(Brassicacee)

Mais dolce

Melanzana

Pastinaca

Peperone

Pepino

Piselli

Pomodori

Porro

Prezzemolo tuberoso

Rafano rusticana /

Ramolaccio

Ramolaccio

Rapa di Brassica rapa e

B. napus

Ravanello

Rucola

Scalogni

Scorzonera

Sedano rapa

Nottue terricole o

vermi grigi

Concentrazione: 0.05 %

Dose: 0.5 l/ha

Termine d'attesa: 2 Settimane

3, 4, 5, 6

A

Coltura

Agente

patogeno/Efficacia

Dosaggio

Restrizioni

Spinaci

Topinambur

Tuberina

Valerianella

Serra: Asparagi

Serra: Rabarbaro

Aleurodidi

Dose: 0.5 l/ha

Applicazione: Dopo il raccolto.

3, 4, 7

Asparagi

Rabarbaro

Nottue terricole o

vermi grigi

Dose: 0.5 l/ha

Applicazione: Dopo il raccolto.

3, 4, 5, 7

G Carote

Afidi

Psilla della carota

Dose: 0.3 l/ha

Termine d'attesa: 2 Settimane

3, 4, 6, 8

Carote

Pastinaca

Prezzemolo tuberoso

Sedano rapa

Mosca della carota

Dose: 1 l/ha

Termine d'attesa: 4 Settimane

3, 4, 5, 9

G Cavoli fogliacei

Nottue terricole o

vermi grigi

Dose: 0.3 l/ha

Termine d'attesa: 2 Settimane

3, 4, 6, 8

Cipolle

Porro

Tripidi

Dose: 0.3 l/ha

Termine d'attesa: 2 Settimane

3, 4, 6, 8

Serra: Cipollotti a

mazzi

Aleurodidi

Dose: 0.5 l/ha

Termine d'attesa: 1 Settimane

3, 4, 6

G Fagioli

piralide delle

leguminose

Sfingi

Dose: 0.3 l/ha

Termine d'attesa: 2 Settimane

3, 4, 8, 10

Serra: Funghi

commestibili

Sciaridi

Dose: 0.5 ml/m²

Termine d'attesa: 3 Settimane

4, 11

G Piselli senza baccello

Tortrice del pisello

Dose: 0.3 l/ha

Termine d'attesa: 2 Settimane

3, 4, 6, 8

G Specie di cavoli

Cavolaie

Cecidomia del cavolo

Nottue (defogliatrici)

Punteruolo degli steli

di cavoli

Punteruolo delle galle

dei cavoli

Dose: 0.3 l/ha

Termine d'attesa: 2 Settimane

3, 4, 6, 8

Barbabietola da

zucchero

Altiche della

barbabietola

Dose: 0.3 l/ha

Termine d'attesa: 6 Settimane

3, 4, 8, 12

F Barbabietola da

Nottue terricole o

Dose: 0.5 l/ha

3, 4, 5, 12

A

Coltura

Agente

patogeno/Efficacia

Dosaggio

Restrizioni

zucchero

vermi grigi

Termine d'attesa: 6 Settimane

F Cereali

Cloropo del grano

Dose: 0.3 l/ha

Termine d'attesa: 6 Settimane

3, 4, 8, 13

F Cereali autunnali

Afidi vettori di virus

Dose: 0.3 l/ha

Applicazione: In autunno.

3, 4, 8, 13

F Colza

Punteruolo delle

silique delle crocifere

Azione parziale:

Cecidomia delle silique

delle crocifere

Dose: 0.3 l/ha

Termine d'attesa: 6 Settimane

Applicazione: Fino allo stadio fine

sviluppo dei bottoni fiorali. (BBCH

59).

3, 4, 8, 13

F Colza

Punteruolo degli steli

della colza

Dose: 0.4 l/ha

Termine d'attesa: 6 Settimane

Applicazione: Stadi 31-53 (BBCH).

3, 4, 5, 13

F Colza autunnale

Altica della colza

Tentredine delle

crocifere

Dose: 0.3 l/ha

Applicazione: In autunno.

3, 4, 8, 13

F Luppolo

Afidi

Concentrazione: 0.03 %

Termine d'attesa: 3 Settimane

3, 4, 5, 14

F Mais

Mosca frit

Dose: 0.3 l/ha

Termine d'attesa: 6 Settimane

3, 4, 8, 12

F Patate

Dorifora della patata

Dose: 0.3 l/ha

Termine d'attesa: 3 Settimane

3, 4, 8, 15

F Pisello proteico

Tortrice del pisello

Dose: 0.3 l/ha

Termine d'attesa: 2 Settimane

3, 4, 6, 8

F Soia

Vanessa del cardo

Dose: 0.3 l/ha

Termine d'attesa: 2 Settimane

3, 4, 8, 12

Colture da fiore e

piante verdi

Afidi

Aleurodidi

Cocciniglie del genere

lecanio

Crisomelidi

Larve defogliatrici

Nottue terricole o

vermi grigi

Tripidi

Concentrazione: 0.05 %

3, 4, 5, 16,

Restrizioni e osservazioni:

Al massimo 2 trattamenti per anno e particella.

Per i lamponi estivi la dose indicata si riferisce allo stadio "inizio fioritura fino a 50% dei fiori

aperti", trattamento con una quantità standard di poltiglia di 1000 l/ha. Per i lamponi autunnali la

dose si riferisce ad una siepe di 150 - 170 cm d'altezza, trattamento con una quantità standard di

poltiglia di 1000 l/ha.

SPe 8: Pericoloso per le api - Può entrare in contatto con piante in fiore o che presentano melata

soltanto di sera, al di fuori del periodo di volo delle api. Applicazione soltanto in serre chiuse, a

condizione che non siano presenti impollinatori.

Durante la preparazione della poltiglia: Indossare guanti di protezione + occhiali di protezione o

una visiera.

SPe 3: Per proteggere organismi acquatici dagli effetti della deriva rispettare una zona tampone

non trattata di 100 metri dalle acque superficiali. Per la protezione contro gli effetti di un

dilavamento, rispettare una zona tampone con copertura vegetale a una distanza di almeno 6 metri.

Riduzione della distanza a causa di deriva ed eccezioni secondo le istruzioni dell'UFAG.

Al massimo 2 trattamenti per coltura con questo prodotto o qualsiasi altro prodotto contenente tale

sostanza attiva.

Al massimo 2 trattamenti per anno e particella con questo prodotto o qualsiasi altro prodotto

contenente tale sostanza attiva

SPe 3: Per proteggere organismi acquatici dagli effetti della deriva rispettare una zona tampone

non trattata di 50 metri dalle acque superficiali. Per la protezione contro gli effetti di un

dilavamento, rispettare una zona tampone con copertura vegetale a una distanza di almeno 6 metri.

Riduzione della distanza a causa di deriva ed eccezioni secondo le istruzioni dell'UFAG.

Trattamenti solo durante il volo (secondo numero critico delle catture) a intervalli di almeno 7

giorni.

10.Al massimo 1 trattamento per coltura con questo prodotto o qualsiasi altro prodotto contenente

tale sostanza attiva

11.Spruzzare o nebulizzare nell'ambiente. Non spruzzare direttamente sulle colture né sui corpi

fruttiferi.

12.Al massimo un 1 trattamento per coltura.

13.Al massimo 1 trattamento per coltura e anno.

14.Al massimo 3 trattamenti per coltura.

15.SPa 1: Per evitare l'insorgere di resistenza non applicare questo o altri prodotti contenenti un

piretroide per più di 1 volta per coltura.

16.Adeguato soltanto contro ceppi non resistenti.

17.Non nebulizzare o vaporizzare.

Caratterizzazione di pericolo:

Si applicano la classificazione e la caratterizzazione dell’etichetta originale estera..

Ulteriori simboli di pericolo svizzeri:

SP 1 Non contaminare l'acqua con il prodotto o il suo imballaggio.

SPe 8 Pericoloso per le api

In caso di dubbio valgono soltanto i documenti originali dell'omologazione. La menzione di un prodotto,

principio attivo o di una ditta non rappresenta alcuna raccomandazione.

5-12-2018

Public health risks associated with food‐borne parasites

Public health risks associated with food‐borne parasites

Published on: Tue, 04 Dec 2018 Parasites are important food‐borne pathogens. Their complex lifecycles, varied transmission routes, and prolonged periods between infection and symptoms mean that the public health burden and relative importance of different transmission routes are often difficult to assess. Furthermore, there are challenges in detection and diagnostics, and variations in reporting. A Europe‐focused ranking exercise, using multicriteria decision analysis, identified potentially food‐borne ...

Europe - EFSA - European Food Safety Authority Publications

14-1-2019


Opinion/decision on a Paediatric investigation plan (PIP): Luspatercept, decision type: , therapeutic area: , PIP number: P/0254/2018

Opinion/decision on a Paediatric investigation plan (PIP): Luspatercept, decision type: , therapeutic area: , PIP number: P/0254/2018

Opinion/decision on a Paediatric investigation plan (PIP): Luspatercept, decision type: , therapeutic area: , PIP number: P/0254/2018

Europe - EMA - European Medicines Agency

11-1-2019


Opinion/decision on a Paediatric investigation plan (PIP): Octenidine (dihydrochloride), decision type: , therapeutic area: , PIP number: P/0240/2018

Opinion/decision on a Paediatric investigation plan (PIP): Octenidine (dihydrochloride), decision type: , therapeutic area: , PIP number: P/0240/2018

Opinion/decision on a Paediatric investigation plan (PIP): Octenidine (dihydrochloride), decision type: , therapeutic area: , PIP number: P/0240/2018

Europe - EMA - European Medicines Agency

11-1-2019


Opinion/decision on a Paediatric investigation plan (PIP): Olumiant,baricitinib, decision type: , therapeutic area: , PIP number: P/0291/2018

Opinion/decision on a Paediatric investigation plan (PIP): Olumiant,baricitinib, decision type: , therapeutic area: , PIP number: P/0291/2018

Opinion/decision on a Paediatric investigation plan (PIP): Olumiant,baricitinib, decision type: , therapeutic area: , PIP number: P/0291/2018

Europe - EMA - European Medicines Agency

11-1-2019


Opinion/decision on a Paediatric investigation plan (PIP): Kevzara,sarilumab, decision type: , therapeutic area: , PIP number: P/0335/2018

Opinion/decision on a Paediatric investigation plan (PIP): Kevzara,sarilumab, decision type: , therapeutic area: , PIP number: P/0335/2018

Opinion/decision on a Paediatric investigation plan (PIP): Kevzara,sarilumab, decision type: , therapeutic area: , PIP number: P/0335/2018

Europe - EMA - European Medicines Agency

11-1-2019


Opinion/decision on a Paediatric investigation plan (PIP): Clostridium Botulinum neurotoxin type A (150 kD), free from complexing proteins, decision type: , therapeutic area: , PIP number: P/0338/2018

Opinion/decision on a Paediatric investigation plan (PIP): Clostridium Botulinum neurotoxin type A (150 kD), free from complexing proteins, decision type: , therapeutic area: , PIP number: P/0338/2018

Opinion/decision on a Paediatric investigation plan (PIP): Clostridium Botulinum neurotoxin type A (150 kD), free from complexing proteins, decision type: , therapeutic area: , PIP number: P/0338/2018

Europe - EMA - European Medicines Agency

11-1-2019


Opinion/decision on a Paediatric investigation plan (PIP): Adcetris,Brentuximab vedotin, decision type: , therapeutic area: , PIP number: P/0327/2018

Opinion/decision on a Paediatric investigation plan (PIP): Adcetris,Brentuximab vedotin, decision type: , therapeutic area: , PIP number: P/0327/2018

Opinion/decision on a Paediatric investigation plan (PIP): Adcetris,Brentuximab vedotin, decision type: , therapeutic area: , PIP number: P/0327/2018

Europe - EMA - European Medicines Agency

11-1-2019


Opinion/decision on a Paediatric investigation plan (PIP): Veliparib, decision type: , therapeutic area: , PIP number: P/0256/2018

Opinion/decision on a Paediatric investigation plan (PIP): Veliparib, decision type: , therapeutic area: , PIP number: P/0256/2018

Opinion/decision on a Paediatric investigation plan (PIP): Veliparib, decision type: , therapeutic area: , PIP number: P/0256/2018

Europe - EMA - European Medicines Agency

11-1-2019


Opinion/decision on a Paediatric investigation plan (PIP): navitoclax, decision type: , therapeutic area: , PIP number: P/0255/2018

Opinion/decision on a Paediatric investigation plan (PIP): navitoclax, decision type: , therapeutic area: , PIP number: P/0255/2018

Opinion/decision on a Paediatric investigation plan (PIP): navitoclax, decision type: , therapeutic area: , PIP number: P/0255/2018

Europe - EMA - European Medicines Agency

20-12-2018

Namuscla (Lupin Europe GmbH)

Namuscla (Lupin Europe GmbH)

Namuscla (Active substance: Mexiletine) - New authorisation - Commission Decision (2018)9133 of Thu, 20 Dec 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/4584

Europe -DG Health and Food Safety

20-12-2018

Bevespi Aerosphere (AstraZeneca AB)

Bevespi Aerosphere (AstraZeneca AB)

Bevespi Aerosphere (Active substance: glycopyrronium bromide / formoterol) - New authorisation - Commission Decision (2018)9127 of Thu, 20 Dec 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/4245

Europe -DG Health and Food Safety

19-12-2018

Macugen (PharmaSwiss CeskA republika s.r.o.)

Macugen (PharmaSwiss CeskA republika s.r.o.)

Macugen (Active substance: pegaptanib sodium) - Withdrawal - Commission Decision (2018)9064 of Wed, 19 Dec 2018

Europe -DG Health and Food Safety

19-12-2018

Perlinring and associated names

Perlinring and associated names

Perlinring and associated names (Active substance: etonogestrel/ethinylestradiol) - Community Referrals - Art 29 - Commission Decision (2018)9141 of Wed, 19 Dec 2018 European Medicines Agency (EMA) procedure number: EMEA/H/A-29(4)/1473

Europe -DG Health and Food Safety

19-12-2018


Opinion/decision on a Paediatric investigation plan (PIP): Abraxane,paclitaxel, decision type: , therapeutic area: , PIP number: P/0257/2018

Opinion/decision on a Paediatric investigation plan (PIP): Abraxane,paclitaxel, decision type: , therapeutic area: , PIP number: P/0257/2018

Opinion/decision on a Paediatric investigation plan (PIP): Abraxane,paclitaxel, decision type: , therapeutic area: , PIP number: P/0257/2018

Europe - EMA - European Medicines Agency

17-12-2018

OCALIVA (Intercept Pharma Ltd)

OCALIVA (Intercept Pharma Ltd)

OCALIVA (Active substance: obeticholic acid) - Centralised - Annual renewal - Commission Decision (2018)8909 of Mon, 17 Dec 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/4093/R/9

Europe -DG Health and Food Safety

14-12-2018

Desloratadine Teva (Teva B.V.)

Desloratadine Teva (Teva B.V.)

Desloratadine Teva (Active substance: desloratadine) - Centralised - Yearly update - Commission Decision (2018)8912 of Fri, 14 Dec 2018

Europe -DG Health and Food Safety

14-12-2018

Revinty Ellipta (GlaxoSmithKline (Ireland) Limited)

Revinty Ellipta (GlaxoSmithKline (Ireland) Limited)

Revinty Ellipta (Active substance: fluticasone furoate / vilanterol) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)8927 of Fri, 14 Dec 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/2745/T/38

Europe -DG Health and Food Safety

14-12-2018

Valdoxan (Les Laboratoires Servier)

Valdoxan (Les Laboratoires Servier)

Valdoxan (Active substance: agomelatine) - Centralised - Renewal - Commission Decision (2018)8932 of Fri, 14 Dec 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/915/R/42

Europe -DG Health and Food Safety

14-12-2018

Ogivri (Mylan S.A.S.)

Ogivri (Mylan S.A.S.)

Ogivri (Active substance: trastuzumab) - Centralised - Authorisation - Commission Decision (2018)8913 of Fri, 14 Dec 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/4916

Europe -DG Health and Food Safety

14-12-2018

LONGRANGE (Merial)

LONGRANGE (Merial)

LONGRANGE (Active substance: eprinomectin) - Refusal of authorisation - Commission Decision (2018)8905 of Fri, 14 Dec 2018 European Medicines Agency (EMA) procedure number: EMEA/V/C/4291

Europe -DG Health and Food Safety

14-12-2018

Relvar Ellipta (GlaxoSmithKline (Ireland) Limited)

Relvar Ellipta (GlaxoSmithKline (Ireland) Limited)

Relvar Ellipta (Active substance: fluticasone furoate/vilanterol) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)8928 of Fri, 14 Dec 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/2673/T/40

Europe -DG Health and Food Safety

14-12-2018

Dengvaxia (Sanofi Pasteur)

Dengvaxia (Sanofi Pasteur)

Dengvaxia (Active substance: dengue tetravalent vaccine (live, attenuated)) - Centralised - Authorisation - Commission Decision (2018)8933 of Fri, 14 Dec 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/4171

Europe -DG Health and Food Safety

14-12-2018

Flucelvax Tetra (Seqirus Netherlands B.V.)

Flucelvax Tetra (Seqirus Netherlands B.V.)

Flucelvax Tetra (Active substance: influenza vaccine (surface antigen, inactivated, prepared in cell cultures)) - Centralised - Authorisation - Commission Decision (2018)8911 of Fri, 14 Dec 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/4814

Europe -DG Health and Food Safety

14-12-2018

Pregabalin Pfizer (Pfizer Europe MA EEIG)

Pregabalin Pfizer (Pfizer Europe MA EEIG)

Pregabalin Pfizer (Active substance: pregabalin) - Centralised - Renewal - Commission Decision (2018)8908 of Fri, 14 Dec 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/3880/R/25

Europe -DG Health and Food Safety

13-12-2018

voriconazole

voriconazole

voriconazole (Active substance: voriconazole) - Centralised - Art 28 - (PSUR - Commission Decision (2018)8915 of Thu, 13 Dec 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/PSUSA/3127/201802

Europe -DG Health and Food Safety

12-12-2018

Oncaspar (Les Laboratoires Servier)

Oncaspar (Les Laboratoires Servier)

Oncaspar (Active substance: pegaspargase) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)8757 of Wed, 12 Dec 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/3789/T/21

Europe -DG Health and Food Safety

12-12-2018

Daklinza (Bristol-Myers Squibb Pharma EEIG)

Daklinza (Bristol-Myers Squibb Pharma EEIG)

Daklinza (Active substance: daclatasvir) - Centralised - Yearly update - Commission Decision (2018)8758 of Wed, 12 Dec 2018

Europe -DG Health and Food Safety

12-12-2018

EVOTAZ (Bristol-Myers Squibb Pharma EEIG)

EVOTAZ (Bristol-Myers Squibb Pharma EEIG)

EVOTAZ (Active substance: atazanavir / cobicistat) - Centralised - Yearly update - Commission Decision (2018)8679 of Wed, 12 Dec 2018

Europe -DG Health and Food Safety

12-12-2018

Elocta (Swedish Orphan Biovitrum AB (publ))

Elocta (Swedish Orphan Biovitrum AB (publ))

Elocta (Active substance: efmoroctocog alfa) - Centralised - Variation - Commission Decision (2018)8678 of Wed, 12 Dec 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/3964/X/21

Europe -DG Health and Food Safety

11-12-2018

Final scheduling decisions and reasons: NCEs and Appendix H

Final scheduling decisions and reasons: NCEs and Appendix H

Delegate only final scheduling decisions on NCEs and Appendix H are now available

Therapeutic Goods Administration - Australia

11-12-2018

Tenofovir disoproxil Zentiva (Zentiva, k.s.)

Tenofovir disoproxil Zentiva (Zentiva, k.s.)

Tenofovir disoproxil Zentiva (Active substance: tenofovir disoproxil) - Centralised - Yearly update - Commission Decision (2018)8683 of Tue, 11 Dec 2018

Europe -DG Health and Food Safety

11-12-2018

Ziagen (ViiV Healthcare BV)

Ziagen (ViiV Healthcare BV)

Ziagen (Active substance: abacavir sulfate) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)8685 of Tue, 11 Dec 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/252/T/104

Europe -DG Health and Food Safety

11-12-2018

Xermelo (Ipsen Pharma)

Xermelo (Ipsen Pharma)

Xermelo (Active substance: telotristat) - Centralised - Yearly update - Commission Decision (2018)8684 of Tue, 11 Dec 2018

Europe -DG Health and Food Safety

11-12-2018

Rubraca (Clovis Oncology Ireland Limited)

Rubraca (Clovis Oncology Ireland Limited)

Rubraca (Active substance: rucaparib) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)8686 of Tue, 11 Dec 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/4272/T/5

Europe -DG Health and Food Safety

11-12-2018

Aivlosin (ECO Animal Health Ltd)

Aivlosin (ECO Animal Health Ltd)

Aivlosin (Active substance: Tylvalosin) - Centralised - Yearly update - Commission Decision (2018)8687 of Tue, 11 Dec 2018

Europe -DG Health and Food Safety

10-12-2018

Exondys (AVI BioPharma International Ltd)

Exondys (AVI BioPharma International Ltd)

Exondys (Active substance: eteplirsen) - Centralised - Refusal of marketing authorisation - Commission Decision (2018)8620 of Mon, 10 Dec 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/4355

Europe -DG Health and Food Safety

10-12-2018

Ivabradine JensonR (JensonR+ Limited)

Ivabradine JensonR (JensonR+ Limited)

Ivabradine JensonR (Active substance: ivabradine) - Centralised - Withdrawal - Commission Decision (2018)8623 of Mon, 10 Dec 2018

Europe -DG Health and Food Safety

10-12-2018

EU/3/16/1662 (QRC Ireland)

EU/3/16/1662 (QRC Ireland)

EU/3/16/1662 (Active substance: H-Phe-Ser-Arg-Tyr-Ala-Arg-OH acetate) - Transfer of orphan designation - Commission Decision (2018)8626 of Mon, 10 Dec 2018 European Medicines Agency (EMA) procedure number: EMA/OD/011/16/T/01

Europe -DG Health and Food Safety

10-12-2018

EU/3/17/1906 (PTC Therapeutics International Limited)

EU/3/17/1906 (PTC Therapeutics International Limited)

EU/3/17/1906 (Active substance: Recombinant adeno-associated viral vector serotype 5 carrying the gene for the human frataxin protein) - Transfer of orphan designation - Commission Decision (2018)8634 of Mon, 10 Dec 2018 European Medicines Agency (EMA) procedure number: EMA/OD/0000002509

Europe -DG Health and Food Safety

10-12-2018

EU/3/16/1786 (PTC Therapeutics International Limited)

EU/3/16/1786 (PTC Therapeutics International Limited)

EU/3/16/1786 (Active substance: Recombinant adeno-associated viral vector serotype 2 carrying the gene for the human aromatic L-amino acid decarboxylase protein) - Transfer of orphan designation - Commission Decision (2018)8630 of Mon, 10 Dec 2018 European Medicines Agency (EMA) procedure number: EMA/OD/0000002507

Europe -DG Health and Food Safety

10-12-2018

EU/3/16/1651 (PTC Therapeutics International Limited)

EU/3/16/1651 (PTC Therapeutics International Limited)

EU/3/16/1651 (Active substance: Recombinant adeno-associated viral vector serotype 9 carrying the gene for the human E6-AP ubiquitin protein ligase) - Transfer of orphan designation - Commission Decision (2018)8632 of Mon, 10 Dec 2018 European Medicines Agency (EMA) procedure number: EMA/OD/0000002508

Europe -DG Health and Food Safety

10-12-2018

EU/3/16/1802 (FGK Representative Service GmbH)

EU/3/16/1802 (FGK Representative Service GmbH)

EU/3/16/1802 (Active substance: Ivosidenib) - Transfer of orphan designation - Commission Decision (2018)8627 of Mon, 10 Dec 2018 European Medicines Agency (EMA) procedure number: EMA/OD/0000002422

Europe -DG Health and Food Safety

10-12-2018

EU/3/10/760 (TESARO Bio Netherlands B.V.)

EU/3/10/760 (TESARO Bio Netherlands B.V.)

EU/3/10/760 (Active substance: (3S)-3-{4-[7-(aminocarbonyl)-2H-indazol-2-yl] phenyl} piperidine tosylate monohydrate salt) - Transfer of orphan designation - Commission Decision (2018)8636 of Mon, 10 Dec 2018 European Medicines Agency (EMA) procedure number: EMA/OD/0000002385

Europe -DG Health and Food Safety

10-12-2018

EU/3/17/1893 (SFL Regulatory Services GmbH)

EU/3/17/1893 (SFL Regulatory Services GmbH)

EU/3/17/1893 (Active substance: Polyphenyl(disodium 3-O-sulfo-beta-D-glucopyranuronate)-(1?3)-beta-D-galactopyranoside) - Transfer of orphan designation - Commission Decision (2018)8628 of Mon, 10 Dec 2018 European Medicines Agency (EMA) procedure number: EMA/OD/048/17/T/01

Europe -DG Health and Food Safety

10-12-2018

EU/3/09/628 (Nova Laboratories Ireland Limited)

EU/3/09/628 (Nova Laboratories Ireland Limited)

EU/3/09/628 (Active substance: Mercaptopurine (oral suspension)) - Transfer of orphan designation - Commission Decision (2018)8629 of Mon, 10 Dec 2018 European Medicines Agency (EMA) procedure number: EMA/OD/0000002301

Europe -DG Health and Food Safety

10-12-2018

EU/3/11/933 (Les Laboratoires Servier)

EU/3/11/933 (Les Laboratoires Servier)

EU/3/11/933 (Active substance: Nanoliposomal irinotecan) - Transfer of orphan designation - Commission Decision (2018)8625 of Mon, 10 Dec 2018 European Medicines Agency (EMA) procedure number: EMA/OD/051/11/T/02

Europe -DG Health and Food Safety

7-12-2018

Olanzapine Mylan (Mylan S.A.S.)

Olanzapine Mylan (Mylan S.A.S.)

Olanzapine Mylan (Active substance: Olanzapine) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)7622 of Fri, 07 Dec 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/961/T/45

Europe -DG Health and Food Safety

5-12-2018

Luxturna (Spark Therapeutics Ireland Ltd)

Luxturna (Spark Therapeutics Ireland Ltd)

Luxturna (Active substance: voretigene neparvovec) - Centralised - Authorisation - Commission Decision (2018)7970 of Wed, 05 Dec 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/4451

Europe -DG Health and Food Safety

2-12-2018

As a science-based agency we rely on evidence generated from data to inform regulatory decisions. #FDA's #SundayTweetorial discusses how we use data from real-world settings to enhance what we know about medical products. This week we'll announce policies

As a science-based agency we rely on evidence generated from data to inform regulatory decisions. #FDA's #SundayTweetorial discusses how we use data from real-world settings to enhance what we know about medical products. This week we'll announce policies

As a science-based agency we rely on evidence generated from data to inform regulatory decisions. #FDA's #SundayTweetorial discusses how we use data from real-world settings to enhance what we know about medical products. This week we'll announce policies to advance these efforts pic.twitter.com/2co2Hz4jUt

FDA - U.S. Food and Drug Administration

30-11-2018


Opinion/decision on a Paediatric investigation plan (PIP): Risankizumab, decision type: , therapeutic area: , PIP number: P/0230/2018

Opinion/decision on a Paediatric investigation plan (PIP): Risankizumab, decision type: , therapeutic area: , PIP number: P/0230/2018

Opinion/decision on a Paediatric investigation plan (PIP): Risankizumab, decision type: , therapeutic area: , PIP number: P/0230/2018

Europe - EMA - European Medicines Agency

30-11-2018


Opinion/decision on a Paediatric investigation plan (PIP): Risankizumab, decision type: , therapeutic area: , PIP number: P/0231/2018

Opinion/decision on a Paediatric investigation plan (PIP): Risankizumab, decision type: , therapeutic area: , PIP number: P/0231/2018

Opinion/decision on a Paediatric investigation plan (PIP): Risankizumab, decision type: , therapeutic area: , PIP number: P/0231/2018

Europe - EMA - European Medicines Agency

30-11-2018

Pregabalin Zentiva k.s (Zentiva, k.s.)

Pregabalin Zentiva k.s (Zentiva, k.s.)

Pregabalin Zentiva k.s (Active substance: pregabalin) - Centralised - Yearly update - Commission Decision (2018)8149 of Fri, 30 Nov 2018

Europe -DG Health and Food Safety

30-11-2018

Pioglitazone Teva (Teva B.V.)

Pioglitazone Teva (Teva B.V.)

Pioglitazone Teva (Active substance: pioglitazone) - Centralised - Yearly update - Commission Decision (2018)8159 of Fri, 30 Nov 2018

Europe -DG Health and Food Safety

30-11-2018

Keppra (UCB Pharma S.A.)

Keppra (UCB Pharma S.A.)

Keppra (Active substance: levetiracetam) - Centralised - Yearly update - Commission Decision (2018)8160 of Fri, 30 Nov 2018

Europe -DG Health and Food Safety

30-11-2018

Pioglitazone Teva Pharma (Teva B.V.)

Pioglitazone Teva Pharma (Teva B.V.)

Pioglitazone Teva Pharma (Active substance: pioglitazone) - Centralised - Yearly update - Commission Decision (2018)8158 of Fri, 30 Nov 2018

Europe -DG Health and Food Safety

30-11-2018

Public submissions on scheduling matters referred to the ACMS #24 and Joint ACMS-ACCS #19 meetings held in June 2018

Public submissions on scheduling matters referred to the ACMS #24 and Joint ACMS-ACCS #19 meetings held in June 2018

Public submissions on the delegate's interim decision for alkyl nitrites

Therapeutic Goods Administration - Australia

29-11-2018

alli (GlaxoSmithKline Dungarvan Limited)

alli (GlaxoSmithKline Dungarvan Limited)

alli (Active substance: Orlistat) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)8041 of Thu, 29 Nov 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/854/T/59

Europe -DG Health and Food Safety

29-11-2018

Inflacam (Chanelle Pharmaceuticals Manufacturing Limited)

Inflacam (Chanelle Pharmaceuticals Manufacturing Limited)

Inflacam (Active substance: Meloxicam) - Centralised - Variation - Commission Decision (2018)8036 of Thu, 29 Nov 2018 European Medicines Agency (EMA) procedure number: EMEA/V/C/2497/X/15

Europe -DG Health and Food Safety

28-11-2018

Final decisions amending, or not amending, the current Poisons Standard, November 2018

Final decisions amending, or not amending, the current Poisons Standard, November 2018

Final decisions and reasons for medicines and chemicals referred to the June 2018 scheduling meetings

Therapeutic Goods Administration - Australia

28-11-2018


Opinion/decision on a Paediatric investigation plan (PIP): Emapalumab, decision type: , therapeutic area: , PIP number: P/0152/2018

Opinion/decision on a Paediatric investigation plan (PIP): Emapalumab, decision type: , therapeutic area: , PIP number: P/0152/2018

Opinion/decision on a Paediatric investigation plan (PIP): Emapalumab, decision type: , therapeutic area: , PIP number: P/0152/2018

Europe - EMA - European Medicines Agency

28-11-2018


Opinion/decision on a Paediatric investigation plan (PIP): lamivudine,dolutegravir, decision type: , therapeutic area: , PIP number: P/0151/2018

Opinion/decision on a Paediatric investigation plan (PIP): lamivudine,dolutegravir, decision type: , therapeutic area: , PIP number: P/0151/2018

Opinion/decision on a Paediatric investigation plan (PIP): lamivudine,dolutegravir, decision type: , therapeutic area: , PIP number: P/0151/2018

Europe - EMA - European Medicines Agency

28-11-2018


Opinion/decision on a Paediatric investigation plan (PIP): Larotrectinib, decision type: , therapeutic area: , PIP number: P/0182/2018

Opinion/decision on a Paediatric investigation plan (PIP): Larotrectinib, decision type: , therapeutic area: , PIP number: P/0182/2018

Opinion/decision on a Paediatric investigation plan (PIP): Larotrectinib, decision type: , therapeutic area: , PIP number: P/0182/2018

Europe - EMA - European Medicines Agency

28-11-2018


Opinion/decision on a Paediatric investigation plan (PIP): Fenfluramine (hydrochloride), decision type: , therapeutic area: , PIP number: P/0177/2018

Opinion/decision on a Paediatric investigation plan (PIP): Fenfluramine (hydrochloride), decision type: , therapeutic area: , PIP number: P/0177/2018

Opinion/decision on a Paediatric investigation plan (PIP): Fenfluramine (hydrochloride), decision type: , therapeutic area: , PIP number: P/0177/2018

Europe - EMA - European Medicines Agency

28-11-2018


Opinion/decision on a Paediatric investigation plan (PIP): Rimiducid, decision type: , therapeutic area: , PIP number: P/0186/2018

Opinion/decision on a Paediatric investigation plan (PIP): Rimiducid, decision type: , therapeutic area: , PIP number: P/0186/2018

Opinion/decision on a Paediatric investigation plan (PIP): Rimiducid, decision type: , therapeutic area: , PIP number: P/0186/2018

Europe - EMA - European Medicines Agency